Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
High dose thiamine improves fatigue in multiple sclerosis.
Minocycline treatment for rheumatoid arthritis: an open dose finding study.
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Food and Drug Administration briefing document for ofatumumab
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
FDA approves Ampyra to improve walking in adults with multiple sclerosis
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.
Managing fatigue in patients with multiple sclerosis.
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Pages
« first
‹ previous
…
150
151
152
153
154
155
156
157
158
…
next ›
last »